XML 14 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (1,262,474) $ (1,392,692)
Adjustments to reconcile net loss to net cash used in operating activities    
Bad debt recovery (20,000) (46,000)
Stock-based compensation 74,245 83,728
Amortization of prepaid stock-based compensation 107,970
Net realized gain on equity investments 104,700
Net unrealized loss (gain) loss on equity investments 221,309 (68,750)
Equity shares earned for lock up agreement (85,733)
Gain on forgiveness of PPP note payable and accrued interest (19,082)
Change in operating assets and liabilities:    
Prepaid expenses and other current assets 38,304 (64,047)
Assets of discontinued operations (22,123)
Interest receivable (2,380)
Accounts payable and accrued expenses (262,013) 65,146
Insurance payable 40,819
Deferred revenue (36,051) 514,787
NET CASH USED IN OPERATING ACTIVITIES (1,189,274) (841,063)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Net proceeds from sale of equity investments 66,707
Collection on note receivable 20,000 69,500
NET CASH PROVIDED BY INVESTING ACTIVITIES 86,707 69,500
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from sale of preferred stock 3,794,102
Advance from a related party 2,366
Repayment of advance from a related party (2,366)
NET CASH PROVIDED BY FINANCING ACTIVITIES 3,794,102
NET CHANGE IN CASH AND CASH EQUIVALENTS: (1,102,567) 3,022,539
CASH AND CASH EQUIVALENTS - beginning of the period 9,837,001 1,128,389
CASH AND CASH EQUIVALENTS - end of the period 8,734,434 4,150,928
Cash paid during the period for:    
Interest 224
Income taxes 25,159
Non-cash investing and financing activities:    
Common stock issued for conversion of Series C preferred stock 76
Iniital fair value of stock options issued as stock-based compensation recorded as deferred compensation 89,546
Common stock warrants granted for services 83,728
Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement $ 531,250